15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Cytosorbents Crp, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $0.75 to $10.00 (about 13.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $5.38 sits 1393% above the current $0.36. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.04 next quarter toward $0.00 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Cytosorbents Crp.
As of Aug, 1 of 2 firms rate CTSO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CTSO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.04
Range $-0.04 – $-0.03 · 2 analysts · -61% YoY
Next period, 2 analysts expect Cytosorbents Crp to earn $-0.04 a share (range $-0.04 – $-0.03), versus $-0.09 a year earlier. Full-year consensus is $-0.22, growing to $0.00 the year after.
REVENUE · NEXT QUARTER
$10.5M
Range $9.9M – $11.0M · 2 analysts · +13% YoY
Revenue is expected to reach $10.5M (range $9.9M – $11.0M), +13.3% year-over-year. Full-year consensus is $38.9M, rising to $44.2M next year.
Top analysts covering Cytosorbents Crp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CTSO.
#1
Sean Lee
HC Wainwright & Co. · Rank #222
Hold
$0.75+108.3% to target
Overall win rate
44%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #407
Buy
$10.00+2677.8% to target
Overall win rate
22%
+ Follow
#3
Jason Kolbert
EF Hutton
Buy
$10.00+2677.8% to target
Coverage
—
+ Follow
CTSO stock forecast FAQ
What is CTSO's average 12-month price target?+
The 2 analysts with a live target average $5.38 for Cytosorbents Crp over the next 12 months, ranging from a $10.00 high to a $0.75 low.
Is CTSO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CTSO?+
The Street-high target is $10.00 (D. Boral Capital), and the Street-low is $0.75 (HC Wainwright & Co.). The average of all 2 active targets is $5.38.
How many Wall Street analysts cover CTSO?+
2 analysts have an active rating on Cytosorbents Crp, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering CTSO?+
Among analysts who currently cover CTSO, Sean Lee of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #222). Their current call is Hold with a $0.75 target.
What is Cytosorbents Crp's projected EPS for next quarter?+
The consensus estimate is $-0.04 per share (range $-0.04 – $-0.03) across 2 analysts. Full-year EPS is projected at $-0.22, rising to $0.00 the following year.
How much revenue is Cytosorbents Crp expected to report next quarter?+
Consensus revenue is $10.5M (range $9.9M – $11.0M). Full-year revenue is projected at $38.9M, growing to $44.2M next year.
Have analysts been upgrading or downgrading CTSO lately?+
As of Aug, 1 of 2 firms rate CTSO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CTSO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
